Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Mar;90(3):349–354. doi: 10.1111/j.1349-7006.1999.tb00754.x

Circumvention of 5‐Fluorouracil Resistance in Human Stomach Cancer Cells by Uracil Phosphoribosyltransferase Gene Transduction

Makoto Inaba 1, Hiroko Sawada 1, Akiko Sadata 2, Hirofumi Hamada 2,✉
PMCID: PMC5926061  PMID: 10359051

Abstract

A human stomach cancer cell line with acquired resistance to 5‐fluorouracil (5‐FU), NUGC‐3/5FU/L, has been found to possess reduced ability to convert 5‐FU into active metabolites. We attempted in vitro gene therapy for this 5‐FU‐resistant cell line. NUGC‐3 and NUGC‐3/5FU/L cells were infected with recombinant adenovirus (Ad) containing Escherichia coli uracil phosphoribosyltransferase (UPRT) gene driven by CAG promoter (CA), AdCA‐UPRT, and changes in their 5‐FU metabolism and sensitivity were investigated. Activities of orotate phosphoribosyltransferase increased from 10.2 and 1.56 (nmol/mg protein/30 min) in the uninfected cells of NUGC‐3 and NUGC‐3/5FU/L to 216 and 237, respectively, after the transfection of UPRT gene. The 5‐FU nucleotide level in the acid‐insoluble fraction increased from 7.32 to 15.9 (pmol/mg protein) in NUGC‐3 cells on infection with AdCA‐UPRT, and in NUGC‐3/5FU/L cells it increased from 1.91 to 21.4. The 50% growth‐inhibition concentration (IC50) was 12.7 μmol/liter for NUGC‐3 and much higher than 100 μmol/liter for NUGC‐3/5FU/L, indicating over 8‐fold resistance. NUGC‐3/5FU/L transfected with the UPRT gene showed very high sensitivity to 5‐FU with an IC50 of 3.2 μmol/liter. The high resistance in this metabolic activation‐deficient cell line was thus completely reversed by transduction of an exogenous gene coding for a 5‐FU‐anabolizing enzyme.

Keywords: 5‐Fluorouracil, Uracil phosphoribosyltransferase, Drug resistance, Gene therapy, Adenoviral vector

Full Text

The Full Text of this article is available as a PDF (89.2 KB).

REFERENCES

  • 1).Aschele , C. , Sobrero , A. , Faderan , M. A. and Bertino , J. R.Novel mechanism(s) of resistance to 5‐fluorouracil in human colon cancer (HCT‐8) sublines following exposure to two different clinically relevant dose schedules . Cancer Res. , 52 , 1855 – 1864 ( 1992. ). [PubMed] [Google Scholar]
  • 2).Wang , F.‐S. , Aschele , C. , Sobrero , A. , Chang , Y.‐M. and Bertino , J. R.Decreased folypolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance . Cancer Res. , 53 , 3677 – 3680 ( 1993. ). [PubMed] [Google Scholar]
  • 3).Lesuffleur , T. , Kornowski , A. , Luccioni , C. , Muleris , M. , Barbat , A. , Beaumatin , J. , Dussaulx , E. , Dutrillaux , B. and Zweibaum , A.Adaptation to 5‐fluorouracil of the heterogenous human colon tumor cell line HT‐29 results in the selection of cells committed to differentiation . Int. J. Cancer , 49 , 721 – 730 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 4).Copur , S. , Aiba , K. , Drake , J. C. , Allegra , C. J. and Chu , E.Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5‐fluorouracil . Biochem. Pharmacol. , 49 , 1419 – 1426 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 5).Pizzorno , G. and Handschumacher , R. E.Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines . Biochem. Pharmacol. , 49 , 559 – 565 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 6).Findenig , G. , Mader , R. M. , Fritzer‐Szekeres , M. , Steger , G. G. , Jaeger , W. and Szekeres , T.Modulation of 5‐fluorouracil resistance in human colon tumor cell lines by azido‐thymidine . Oncol. Res. , 8 , 189 – 196 ( 1996. ). [PubMed] [Google Scholar]
  • 7).Inaba , M. , Mitsuhashi , J. , Sawada , H. , Miike , N. , Naoe , Y. , Daimon , A. , Koizumi , K. , Tsujimoto , H. and Fukushima , M.Reduced activity of anabolizing enzymes in 5‐fluorouracil‐resistant human stomach cancer cells . Jpn. J. Cancer Res. , 87 , 212 – 220 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8).Inaba , M. , Tanaka , T. and Sawada , H.Increased sensitivity to long‐term 5‐fluorouracil exposure of human colon cancer HT‐29 cells resistant to short‐term exposure . Jpn. J. Cancer Res. , 89 , 323 – 327 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9).Inaba , M. , Naoe , Y. and Mitsuhashi , J.Mechanisms for 5‐fluorouracil resistance in human colon cancer DLD‐1 cells . Biol. Pharm. Bull. , 21 , 569 – 573 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 10).Roth , J. A. and Cristiano , R. J.Gene therapy for cancer: what have we done and where are we going ?. J. Natl. Cancer Inst. , 88 , 21 – 39 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 11).Hapke , D. M. , Stegmann , A. P. A. and Mitchell , B. S.Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity . Cancer Res. , 56 , 2343 – 2347 ( 1996. ). [PubMed] [Google Scholar]
  • 12).Manome , Y. , Wen , P. Y. , Dong , Y. , Tanaka , T. , Mitchell , B. S. , Kufe , D. W. and Fine , H. A.Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo . Nat. Med , 2 , 567 – 573 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 13).Kanai , F. , Kawakami , T. , Hamada , H. , Sadata , A. , Yoshida , Y. , Tanaka , T. , Ohashi , M. , Shiratori , Y. and Omata , M.Adenovirus‐mediated transduction of Escherichia coli uracil phosphoribosyl‐transferase gene sensitizes cancer cells to low concentration of 5‐fluorouracil in vitro and in vivo . Cancer Res , 58 , 1946 – 1951 ( 1998. ). [PubMed] [Google Scholar]
  • 14).Kanai , F. , Shiratori , Y. , Yoshida , Y. , Wakimoto , H. , Hamada , H. , Kanegae , Y. , Saito , I. , Nakabayashi , H. , Tamaoki , T. , Tanaka , T. , Lan , K.‐H. , Kato , N. , Shiina , S. and Omata , M.Gene therapy for α‐fetoprotein producing human hepatoma cells by adenovirus‐mediated transfer of herpes simplex virus thymidine kinase gene . Hepatology , 23 , 1359 – 1368 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 15).Tanaka , T. , Kanai , F. , Okabe , S. , Yoshida , Y. , Wakimoto , H. , Hamada , H. , Shiratori , Y. , Lan , K.‐H. , Ishitobi , M. and Omata , M.Adenovirus‐mediated prodrug gene therapy for carcinoembryonic antigen‐producing human gastric carcinoma cells in vitro . Cancer Res , 56 , 1341 – 1345 ( 1996. ). [PubMed] [Google Scholar]
  • 16).Peters , G. J. , Laurensse , E. , Leyva , A. , Lankelma , J. and Pinedo , H. M.Sensitivity of human, murine, and rat cells to 5‐fluorouracil and 5′‐deoxy‐5‐fluorouridine in relation to drug‐metabolizing enzymes . Cancer Res. , 46 , 20 – 28 ( 1986. ). [PubMed] [Google Scholar]
  • 17).Loenn , U. and Loenn , S.Interaction between 5‐fluorouracil and DNA of human colon adenocarcinoma . Cancer Res. , 44 , 3414 – 3418 ( 1984. ). [PubMed] [Google Scholar]
  • 18).Carmichael , J. , DeGraff , W. G. , Gazdar , A. F. , Minutena , J. D. and Mitchell , J. B.Evaluation of a tetrazolium‐based semiautomated colorimetric assay: assessment of chemosensitivity testing . Cancer Res. , 48 , 589 – 601 ( 1988. ). [PubMed] [Google Scholar]
  • 19).Grant , S.Ara‐C: cellular and molecular pharmacology . In “ Advances in Cancer Research ” vol. 72 , ed. Woude G. F. V. and Klein G. , pp . 197 – 233 ( 1998. ). Academic Press; , New York . [DOI] [PubMed] [Google Scholar]
  • 20).Ruiz van Haperen , V. W. T. , Veerman , G. , Eriksson , S. , Boven , E. , Stegmann , A. P. A. , Hermsen , M. , Vermorken , J. B. , Pinedo , H. M. and Peters , G. J.Development and molecular characterization of a 2′,2′‐difluorodeoxycytidine‐resistant variant of the human ovarian carcinoma cell line A2780 . Cancer Res. , 54 , 4138 – 4143 ( 1994. ). [PubMed] [Google Scholar]
  • 21).Lenz , H.‐J. , Leichman , C. G. , Danenberg , K. D. , Groshen , S. , Cohen , H. , Laine , L. , Crookes , P. , Silberman , H. , Baranda , J. , Garcia , Y. , Li , J. and Leichman , L.Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival . J. Clin. Oncol. , 14 , 176 – 182 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 22).Leichman , C. G. , Lenz , H.‐J. , Leichman , L. , Danenberg , K. , Baranda , J. , Groshen , S. , Boswell , W. , Metzger , R. , Tan , M. and Danenberg , P. V.Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted‐infusion fluorouracil and weekly leucovorin . J. Clin. Oncol. , 15 , 3223 – 3229 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 23).Stegmann , A. P. A. , Honders , W. H. , Willemze , R. , Ruiz van Haperen , V. W. T. and Landegent , J. E.Transfection of wild‐type deoxycytidine kinase (dck) cDNA into an ara‐C and DAC‐resistant rat leukemia cell line of clonal origin fully restores drug sensitivity . Blood , 85 , 1188 – 1194 ( 1995. ). [PubMed] [Google Scholar]
  • 24).Inaba , M. , Mitsuhashi , J. and Ozawa , S.Kinetic analysis of 5‐fluorouracil action against various cancer cells . Jpn. J. Cancer Res. , 81 , 1039 – 1044 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25).Inaba , M. and Mitsuhashi , J.Flow cytometric analysis of cell‐killing actions of 5‐fluorouracil in human colorectal cancer cells . Oncol. Res. , 6 , 303 – 309 ( 1994. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES